Document Detail


Saxagliptin overview: special focus on safety and adverse effects.
MedLine Citation:
PMID:  23137182     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Saxagliptin (see drug summary box) is a glucose-lowering agent that belongs to the class of Dipeptidylpeptidase-4 (DDP-4) inhibitors used in the treatment of T2DM. Clinical efficacy of saxagliptin as single agent as well as in combination with other medications used for the treatment of T2DM has been well established in several randomized trials. Treatment with saxagliptin is effective, generally safe and well tolerated, apart from a small increase in the incidence of infections such as nasopharyngitis. Its use is not associated with increase risk of hypoglycemia and it is weight neutral. Saxagliptin can be used safely in renal failure (with dose adjustment) and in hepatic impairment. When saxagliptin is used in combination with a strong inhibitor of CYP3A4/A5, reduction in the daily dosage is recommended.
AREAS COVERED: This paper briefly discusses efficacy and pharmacokinetics of saxagliptin. The paper highlights in detail saxagliptin-associated adverse effects, drug interactions, its use in patients with renal and hepatic disease and long-term safety concerns.
EXPERT OPINION: Saxagliptin has comparable efficacy with other DPP-4 inhibitors. It is generally safe and well tolerated; however, it requires dose adjustment in renal disease as well as when used with drugs that are strong inhibitor or inducer of CYP3A4/A5 isoforms. Future safety questions regarding immune system and development of cancer still remain to be completely answered.
Authors:
Shamsa Ali; Vivian Fonseca
Publication Detail:
Type:  Journal Article; Review     Date:  2012-11-09
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  12     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-20     Completed Date:  2013-05-29     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  103-9     Citation Subset:  IM    
Affiliation:
Tulane University, Medicine, New Orleans 70112, USA. vfonseca@tulane.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adamantane / adverse effects,  analogs & derivatives*
Animals
Blood Glucose / drug effects,  metabolism
Diabetes Mellitus, Type 2 / blood,  complications,  drug therapy*
Dipeptides / adverse effects*
Dipeptidyl-Peptidase IV Inhibitors / administration & dosage,  adverse effects*,  pharmacokinetics
Drug Dosage Calculations
Drug Interactions
Humans
Kidney Diseases / complications
Liver Diseases / complications
Patient Selection
Risk Assessment
Risk Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Dipeptides; 0/Dipeptidyl-Peptidase IV Inhibitors; 281-23-2/Adamantane; 9GB927LAJW/saxagliptin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pilot Study of High Performance Air Filtration for Classrooms Applications.
Next Document:  In vitro inhibition of angiogenesis by hydroalcoholic extract of oak (Quercus infectoria) acorn shel...